跳至主要内容
临床试验/ISRCTN46158146
ISRCTN46158146已完成未知

A randomised trial to compare the safety, tolerability and efficacy of bi-monthly intermittent preventive treatment with either artesunate plus mefloquine or amodiaquine plus sulfadoxine-pyrimethamine with the standard regimen of daily proguanil for the prevention of malaria and related complications in patients with sickle cell anaemia in Nigeria

Wellcome Trust (UK)0 个研究点目标入组 270 人开始时间: 2011年11月14日最近更新:

试验速览

阶段
未知
状态
已完成
发起方
入组人数
270

研究概览

研究设计

研究类型
Interventional

入排标准

性别
All

入选标准

  • 1. Age 6months or older and >=5kg
  • 2. Sickle cell clinic attendant
  • 3. Both males and females
  • 4. Agree to abide by the study protocol
  • 5. Give informed consent and assent
  • 6. Not acutely sick at the time of recruitment
  • 7. Not having additional chronic disease
  • 8. Haemoglobin (Hb) genotype of SS and SC confirmed by electrophoresis

排除标准

  • 1. Known allergy to any of the antimalarial drugs use in the trial
  • 2. Severe illnesses requiring urgent admission
  • 3. Treatment with sulfadoxine-pyrimethamine or mefloquine in the previous 2 weeks
  • 4. Patients on cotrimoxazole prophylaxis

研究者

发起方
Wellcome Trust (UK)

相似试验